已发表论文

宝藿苷 I  通过 mTOR/S6K1-Caspases/Bcl2/Bax 细胞凋亡信号通路抑制胰腺癌细胞的增殖

 

Authors Ni F, Tang H, Wang C, Zhang H, Zheng C, Zhang N, Chen B, Sun L

Received 27 August 2019

Accepted for publication 6 December 2019

Published 19 December 2019 Volume 2019:11 Pages 10609—10621

DOI https://doi.org/10.2147/CMAR.S228926

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo

Background: Although the incidence of pancreatic cancer has increased markedly, the 5-year survival rate for this disease is considerably low compared with other types of cancer. Moreover, the mortality rate of pancreatic cancer is similar to its incidence rate. Current therapeutic agents exhibit a lack of specificity for pancreatic cancer. Baohuoside I is traditionally used to treat orgasmic disorder and inflammation. However, its role in pancreatic cancer is unknown.
Objective: To explore the effects of Baohuoside I on pancreatic cancer and to study the potential-related molecular mechanism.
Materials and methods: In the present study, the antineoplastic effect of Baohuoside I was investigated with regard to pancreatic cancer via colony formation, transwell and migration assay. The energy metabolism changes of pancreatic cancer were tested by flow cytometry analysis and oxidative phosphorylation and glycolysis assay. The target signaling members were analyzed by Western blot.
Results: Baohuoside I inhibited the cell growth of pancreatic cancer cells. In addition, it affected intracellular energy metabolism to induce cancer cell apoptosis via the mTOR/S6K1 and the caspase/Bcl2/Bax signaling pathways.
Conclusion: The present data provide further insight into the development of novel drugs against pancreatic cancer.
Keywords: Baohuoside I, pancreatic cancer, apoptosis




Figure 4 Baohuoside I reduces glycolysis in pancreatic cancer cells...